Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients.

Seroconversion rates of hepatitis B vaccination with increasing antigen doses, in 77 haemodialysis (HD) patients were studied in randomly divided two groups. The first group received the standard 20 microg recombinant HBsAg (rHBsAg) dose, and the second group 40 microg at the 0, 1st and 2nd months of HD. At the end of the study, there were no statistically significant differences between the two groups in the response rates of protective antibody, but the response was always higher in the second group. On the other hand, strong positive antibody response (> or = 100 mlU/ml) according to dates of each dose were as 7.4%, 13.1%, 28.9% and 42.2% in the first group and 50.0%, 50.0%, 60.0% and 52.9% in the second group respectively, and there were statistically significant differences between the two groups in the first three months. We concluded that vaccination with higher antigen doses resulted in a stronger antibody response in the early period in our HD patients. No HBV infection was observed in these two groups in the study period.

RCT Entities:   Population Interventions Outcomes